| Welcome to the first issue of EBR under the banner of its new owner, Samedan Ltd. Together with Technomark, Samedan is seeking to expand both the breadth and depth of the magazine, whilst maintaining the quality of the content and heightening focus around the key strategic, technological and ethical themes in our industry. With this in mind, in this issue we have aimed to focus on some of the key informatic and proteomic technologies which have received so much attention of late. For those like me, who really wanted to understand the evolution of the technology behind the hype, the interview with Professor Denis Hochstrasser in Geneva gives both an illuminating personal history and a 'beginner's guide' to both. In terms of commercial activities in this area, two of the three meeting reviews (GenomeX and Biomics) give a thorough overview of who is doing what and with whom, as well as what pharmaceutical partners are expecting and beginning to gain. |
